520 followers
RT @NNTonthefly: New NNT→Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. https://t.co/E1p54edhQR
RT @NNTonthefly: New NNT→Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. https://t.co/E1p54edhQR
New NNT→Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. https://t.co/E1p54edhQR
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. #MS J Neurology http://t.co/xcMTD57BU8